ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1665

Efficacy Versus Safety of Prednisone in Lupus Nephritis Since 1988

Tanmayee Bichile1, Laurence S Magder2 and Michelle Petri3, 1Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis and prednisolone, prednisone

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

Morbidity and damage due to prednisone use in the treatment of SLE is recognized, but prednisone has been a requisite of lupus nephritis induction regimens.  We examined, by calendar years, the prednisone exposure and urine protein in lupus nephritis patients in a large single-center cohort.

Methods

We identified 76 SLE patients who had: 1) biopsy-proven Class III or IV lupus nephritis 2) cohort visit prior to their biopsy with elevated urine protein (dip stick of 2+ to 4+) and at least 4 cohort visits in the year following their biopsy.  For each patient, the average daily prednisone dose, urine dipstick, serum cholesterol, and systolic blood pressure in the year following the biopsy were calculated. 

Results

The average daily dose of prednisone  was lower in more recent years, but the average urine protein was better.

Table 1.  Mean prednisone dose and urine dipstick scores in the year following renal biopsy, by calendar year and stratified by urine protein level prior to biopsy.

Urine dipstick measure in the visit prior to biopsy

Year

Number of Patients

Average Daily Prednisone Dose in year following biopsy1

Average score on urine dipstick over the year following biopsy2

2

1988-1999

5

10.2

2.1

2000-2005

10

20.9

1.6

2006-2012

15

7.6

1.3

 

 

 

 

 

3-4

1988-1999

11

19.2

2.7

2000-2005

24

17.1

2.2

2006-2012

11

15.2

1.8

1P-value for differences between years with respect to mean daily dose of prednisone, adjusting for baseline dipstick equals 0.063.

2P-value for difference in mean urine dipstick score by year, adjusting for baseline dipstick score equals 0.047.

Prednisone use above 20mg daily (mean) had a major effect on total cholesterol, but not on systolic blood pressure (mean).

Table 2.  Mean change (from pre-biopsy) in cholesterol and systolic blood pressure by average daily dose of prednisone in the year following biopsy.

Average Daily Prednisone Dose

Sample Size

Mean change in Cholesterol

Mean change in systolic BP

0-9 mg/d

27

-2.3

-2.5

10-19 mg/d

28

-12.3

-5.7

20+

21

25.2

-0.4

Conclusion

Prednisone dose in Class III-IV lupus nephritis has been reduced in recent years, with no deleterious effect on urine protein (in fact there has been improved control of urine dipstick protein).  The effect of prednisone on traditional risk factors was surprising.  Patients receiving more than 20 mg/day of prednisone had a major increase in serum cholesterol. However, in those receiving 10-19 mg/d prednisone, there was a surprising decrease in both cholesterol and systolic blood pressure.


Disclosure:

T. Bichile,
None;

L. S. Magder,
None;

M. Petri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-versus-safety-of-prednisone-in-lupus-nephritis-since-1988/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology